Background: Pediatric-onset systemic lupus erythematosus (SLE) is typically more severe than adult-onset SLE, with a higher incidence of nervous system involvement. Chorea is a relatively rare neurological complication reported in 2.4%-7% of SLE patients. In particular, chorea induced by glucocorticoid dose reduction is even rarer. Herein, we report the case of a girl with SLE, who developed chorea during the process of glucocorticoid therapy reduction.
Case Summary: We describe a 14-year-old girl who was diagnosed with SLE. She was treated with methylprednisolone and rituximab, and her symptoms improved. On the second day after the methylprednisolone dose was reduced according to the treatment guidelines, the patient developed chorea. Her condition improved after adjusting her glucocorticoid regimen.
Conclusion: This case is a reminder that extra attention to chorea is required in SLE patients during glucocorticoid dose reduction.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10698424 | PMC |
| http://dx.doi.org/10.12998/wjcc.v11.i32.7872 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Barriers and supports for Indigenous youth and young adults with childhood- onset chronic health conditions transitioning from pediatric to adult healthcare: a qualitative study.
Int J Equity Health
December 2024
Indigenous Wellness Core, Alberta Health Service, #306 Anderson Hall, 10959-102 Street, Edmonton, T5H 2V1, AB, Canada.
Background: This study examined the experiences of Indigenous youth and young adults with pediatric onset chronic health conditions who had or were about to transition from pediatric to adult healthcare services. Transition is the process by which youth develop the knowledge and self-management skills needed to manage their health condition, ideally beginning around age 12-13 and continuing until the mid-20s. There is a growing body of literature on healthcare transition, but there is an absence of literature on Indigenous youth, who face additional barriers to accessing healthcare relative to non-Indigenous Canadians.
View Article and Find Full Text PDFPediatric-onset hidradenitis suppurativa: a case series of 42 patients.
Postepy Dermatol Alergol
October 2024
Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland.
Introduction: Hidradenitis suppurativa is a chronic, recurring skin condition characterized by inflammation of the terminal hair follicle. It presents as painful, deep-seated, inflamed lesions such as nodules, fistulas, and abscesses. While the mean onset age for hidradenitis suppurativa is typically between 21 and 29 years, the condition can also manifest in childhood.
View Article and Find Full Text PDFEffective calcineurin inhibitor treatment in adult-onset steroid-resistant nephrotic syndrome with a novel splice donor site variant of TRPC6: a case report.
CEN Case Rep
September 2024
Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Transient receptor potential canonical 6 (TRPC6) variants, which were initially detected in adult-onset familial focal segmental glomerulosclerosis (FSGS), were also identified in pediatric-onset one. Here, we present a patient with adult-onset steroid-resistant nephrotic syndrome (SRNS) who harbored a likely pathogenic TRPC6 variant and partially responded to calcineurin inhibitors (CNIs). A 44-year-old woman with stable rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome was presented with nephrotic syndrome.
View Article and Find Full Text PDFThe risk of cancer in pediatric-onset immune-mediated inflammatory diseases - A nationwide study.
J Autoimmun
December 2024
Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital, Amager and Hvidovre Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents, and Adults, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital -Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Departments of Epidemiology and Global Health, Boston University School of Public Health, Boston, USA; Copenhagen Health Complexity Center, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. Electronic address:
Article Synopsis
- Pediatric-onset immune-mediated inflammatory disease (pIMID) significantly raises the long-term risk of various cancers compared to non-affected individuals, with a twofold increase in cancer risk observed.
- A study involving 12,664 pIMID patients revealed that treatments like thiopurines and anti-TNFα are linked to a markedly higher risk of developing lymphoma and skin cancer.
- The findings emphasize the need for tailored immunotherapy and ongoing cancer monitoring for those diagnosed with pIMID.
Increased serum human epididymis protein 4 is associated with disease activity and systemic involvement in pediatric-onset systemic lupus erythematosus.
Front Immunol
September 2024
Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Objective: We aimed to investigate human epididymis protein 4 (HE4) as a potential biomarker in patients with pediatric-onset systemic lupus erythematosus (pSLE), particularly on the association of serum HE4 levels with disease activity and other laboratory tests.
Methods: We included 137 patients with pSLE and 75 age- and sex-matched healthy controls (HCs). Serum HE4 level was measured by a chemiluminescent microparticle on an Abbott ARCHITECT i2000SR Immunoassay Analyzer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!